{
    "clinical_study": {
        "@rank": "134537", 
        "acronym": "ConSeQuent", 
        "arm_group": [
            {
                "arm_group_label": "Paclitaxel coated balloon", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "uncoated PTA catheter", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of the study is to assess the safety and efficacy of the paclitaxelreleasing balloon\n      catheter SeQuent\u00ae Please P to treat de novo and restenotic lesions in the superficial\n      femoral artery and the proximal two segments of the popliteal artery with reference\n      diameters \u2265 4mm & \u2264 7mm and lesion lengths \u2265 4 cm & \u2264 27 cm. It is the intention of this\n      trial to treat suitable target lesions with DCB only."
        }, 
        "brief_title": "Clinical Trial on Peripheral Arteries Treated With SeQuent\u00ae Please P Paclitaxel Coated Balloon Catheter", 
        "completion_date": {
            "#text": "April 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Stenosis", 
            "Restenosis"
        ], 
        "condition_browse": {
            "mesh_term": "Constriction, Pathologic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Willingness to treat the target lesion according to the DCB only concept\n\n          -  Patients in Rutherford classes 2 through 4 (corresponding to Fontaine stage IIb to\n             III)\n\n          -  Patients eligible for peripheral revascularization by means of PTA\n\n          -  Patients must be \u2265 18 years of age\n\n          -  Patients who are mentally and linguistically able to understand the aim of the study\n             and to show sufficient compliance in following the study protocol\n\n          -  Patients must agree to undergo the 6-month angiographic and clinical follow-up\n\n          -  Patients must agree to undergo the 1 and 2 year clinical follow-up\n\n          -  Patient is able to verbally acknowledge an understanding of the associated risks,\n             benefits, and treatment alternatives to therapeutic options of this trial. The\n             patients, by providing their informed consent, agree to these risks and benefits as\n             stated in the patient informed consent document.\n\n          -  Peripheral lesions in the native SFA or popliteal artery with reference vessel\n             diameters between \u2265 4.0 and \u2264 7.0 mm, lesions lengths \u2265 4 cm and \u2264 27 cm as\n             angiographically documented\n\n          -  Diameter stenosis pre-procedure must be \u2265 70%\n\n          -  Target lesion in the SFA or popliteal artery (first two proximal segments)*.\n\n             * as far as applicable distance of the target lesion to a previously implanted stent\n             should be about 1cm\n\n          -  Vessels must have adequate runoff with at least one vessel to the foot.\n\n          -  Treatment of max. two lesions is permitted.\n\n        Exclusion Criteria:\n\n          -  Patients with Rutherford class 5 or 6\n\n          -  Women who are known or suspected to be pregnant. Hence, patients will be advised to\n             use an adequate birth control method up to and including the 6-month follow-up.\n\n          -  Patients with an expected life span of less than 24 months\n\n          -  Patients with bleeding diathesis in whom anticoagulation or anti-platelet medication\n             is contraindicated\n\n          -  Patients who had a cerebral stroke < 6 months prior to the procedure\n\n          -  Patients with unstable angina pectoris\n\n          -  Patients with acute myocardial infarction within the past 2 weeks\n\n          -  Patient participates in other clinical trials involving any investigational device or\n             drug that interfere with the effects to be studied in this trial.\n\n          -  Interventional treatment at the contralateral leg within 2 weeks prior to or after\n             the study intervention\n\n          -  Untreated hyperthyroidism\n\n          -  Patient has presence or history of severe renal failure (GFR < 30ml/min) and is\n             therefore not eligible for angiography.\n\n          -  Post transplantation of any organ or immune suppressive medication\n\n          -  Other disease to jeopardize follow-up (e.g. malignoma)\n\n          -  Addiction to any drug or to alcohol (WHO definition)\n\n          -  Patients with clinically significant aneurysmal disease of the popliteal, femoral or\n             iliac artery and patients with history of clinically significant abdominal aortic\n             aneurysm\n\n          -  Patients with any type of surgical/interventional procedures within 4 weeks prior to\n             or planned after study intervention (if those may interfere with the peripheral study\n             intervention and/or patient's ability to perform the follow up examinations)\n\n          -  Conditions which prevent the intake of the double anti-platelet therapy for two\n             months\n\n          -  Patients with contraindication for drug-eluting balloon angioplasty given in the\n             instruction for use\n\n          -  Patients under administrative or judicial custody (\u00a720 Act on Medical Devices,\n             Germany)\n\n          -  Strongly calcified lesions with circumferential presence of calcifications and a\n             lesion length of > 4 cm\n\n          -  Chronic total occlusions longer than 10 cm\n\n          -  Lesion below the knee requiring treatment\n\n          -  Target lesion within a bypass graft\n\n          -  In-stent restenosis\n\n          -  Lesions treated with DCB\n\n          -  Concomitant use of atherectomy, cryoplasty or laser therapy\n\n          -  Inflow lesion (proximal to the study lesion) with flow limitation not being\n             successfully treated prior to the study lesion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01970579", 
            "org_study_id": "AAG-G-H-1214"
        }, 
        "intervention": [
            {
                "arm_group_label": "Paclitaxel coated balloon", 
                "description": "Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD\nEach study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)\nTreatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)\nIf two treatment balloons are necessary overlap between the balloon must be 10 mm\nInflation pressure 7-10 atm\nIntraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting", 
                "intervention_name": "Paclitaxel coated balloon", 
                "intervention_type": "Device", 
                "other_name": [
                    "SeQuent\u00ae Please P", 
                    "Drug coated balloon"
                ]
            }, 
            {
                "arm_group_label": "uncoated PTA catheter", 
                "description": "Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD\nEach study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)\nTreatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)\nIf two treatment balloons are necessary overlap between the balloon must be 10 mm\nInflation pressure 7-10 atm\nIntraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting.", 
                "intervention_name": "uncoated PTA catheter", 
                "intervention_type": "Device", 
                "other_name": "POBA"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Paclitaxel"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 19, 2013", 
        "location": [
            {
                "contact": {
                    "email": "m.werk@mlk-berlin.de", 
                    "last_name": "Michael Werk, MD", 
                    "phone": "+49 30 8955 3404"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "14193"
                    }, 
                    "name": "Martin-Luther-Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Werk, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "d.r.meyer@ekh-berlin.de", 
                    "last_name": "Dirk-R. Meyer, MD", 
                    "phone": "+49 030 81008 765"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "14129"
                    }, 
                    "name": "Ev. Krankenhaus Hubertus"
                }, 
                "investigator": {
                    "last_name": "Dirk-R. Meyer, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "thomas.albrecht@vivantes.de", 
                    "last_name": "Thomas Albrecht, MD", 
                    "phone": "+49 030 130 14 2071"
                }, 
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany", 
                        "zip": "12351"
                    }, 
                    "name": "Vivantes Klinikum Neuk\u00f6lln"
                }, 
                "investigator": {
                    "last_name": "Thomas Albrecht, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "ulf.redlich@klinikum-magdeburg.de", 
                    "last_name": "Ulf Redlich, MD", 
                    "phone": "+49 391 791 3701"
                }, 
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany", 
                        "zip": "39130"
                    }, 
                    "name": "Klinikum Magdeburg"
                }, 
                "investigator": {
                    "last_name": "Ulf Redlich, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jens.ricke@med.ovgu.de", 
                    "last_name": "Jens Ricke, MD", 
                    "phone": "+49 391 67 13030"
                }, 
                "facility": {
                    "address": {
                        "city": "Magdeburg", 
                        "country": "Germany", 
                        "zip": "39120"
                    }, 
                    "name": "Klinikum der Otto-von-Guericke-Universit\u00e4t Magdeburg"
                }, 
                "investigator": {
                    "last_name": "Jens Ricke, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ott@dhm.mhn.de", 
                    "last_name": "Ilka Ott, MD", 
                    "phone": "+49 89 1218 4073"
                }, 
                "facility": {
                    "address": {
                        "city": "M\u00fcnchen", 
                        "country": "Germany", 
                        "zip": "80636"
                    }, 
                    "name": "Deutsches Herzzentrum M\u00fcnchen"
                }, 
                "investigator": {
                    "last_name": "Ilka Ott, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "gunnar.tepe@ro-med.de", 
                    "last_name": "Gunnar Tepe, MD", 
                    "phone": "+49 8031 365 3551"
                }, 
                "facility": {
                    "address": {
                        "city": "Rosenheim", 
                        "country": "Germany", 
                        "zip": "83022"
                    }, 
                    "name": "RoMed Klinikum Rosenheim"
                }, 
                "investigator": {
                    "last_name": "Gunar Tepe, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Clinical Trial on Peripheral Arteries Treated With SeQuent\u00ae Please P Paclitaxel Coated Balloon Catheter", 
        "overall_contact": {
            "email": "bettina.kelsch@charite.de", 
            "last_name": "Bettina Kelsch", 
            "phone": "+49 30 450 527 099"
        }, 
        "overall_official": {
            "affiliation": "Vivantes Klinikum Neuk\u00f6lln, Berlin, Germany", 
            "last_name": "Thomas Albrecht, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Late Lumen Loss", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01970579"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "B. Braun Melsungen AG", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "B. Braun Melsungen AG", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}